NNT in screening programs US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for NNT in screening programs. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
NNT in screening programs US Medical PG Question 1: A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
- A. Late-look bias
- B. Latency period (Correct Answer)
- C. Confounding
- D. Effect modification
- E. Pygmalion effect
NNT in screening programs Explanation: ***Latency period***
- **Lung cancer** typically has a **long latency period**, often **20-30+ years**, between initial exposure to tobacco carcinogens and the development of clinically detectable disease.
- A **five-year study duration** in young smokers (ages 20-30) is **far too short** to observe the development of lung cancer, which explains the false negative finding.
- This represents a **fundamental flaw in study design** rather than a bias—the biological timeline of disease development was not adequately considered.
*Late-look bias*
- **Late-look bias** occurs when a study enrolls participants who have already survived the early high-risk period of a disease, leading to **underestimation of true mortality or incidence**.
- Also called **survival bias**, it involves studying a population that has already been "selected" by survival.
- This is not applicable here, as the study simply ended before sufficient time elapsed for disease to develop.
*Confounding*
- **Confounding** occurs when a third variable is associated with both the exposure and outcome, distorting the apparent relationship between them.
- While confounding can affect study results, it would not completely eliminate the detection of a strong, well-established association like smoking and lung cancer in a properly conducted prospective cohort study.
- The issue here is temporal (insufficient follow-up time), not the presence of an unmeasured confounder.
*Effect modification*
- **Effect modification** (also called interaction) occurs when the magnitude of an association between exposure and outcome differs across levels of a third variable.
- This represents a **true biological phenomenon**, not a study design flaw or bias.
- It would not explain the complete failure to detect any association.
*Pygmalion effect*
- The **Pygmalion effect** (observer-expectancy effect) refers to a psychological phenomenon where higher expectations lead to improved performance in the observed subjects.
- This concept is relevant to **behavioral and educational research**, not to objective epidemiological studies of disease incidence.
- It has no relevance to the biological relationship between carcinogen exposure and cancer development.
NNT in screening programs US Medical PG Question 2: Group of 100 medical students took an end of the year exam. The mean score on the exam was 70%, with a standard deviation of 25%. The professor states that a student's score must be within the 95% confidence interval of the mean to pass the exam. Which of the following is the minimum score a student can have to pass the exam?
- A. 45%
- B. 63.75%
- C. 67.5%
- D. 20%
- E. 65% (Correct Answer)
NNT in screening programs Explanation: ***65%***
- To find the **95% confidence interval (CI) of the mean**, we use the formula: Mean ± (Z-score × Standard Error). For a 95% CI, the Z-score is approximately **1.96**.
- The **Standard Error (SE)** is calculated as SD/√n, where n is the sample size (100 students). So, SE = 25%/√100 = 25%/10 = **2.5%**.
- The 95% CI is 70% ± (1.96 × 2.5%) = 70% ± 4.9%. The lower bound is 70% - 4.9% = **65.1%**, which rounds to **65%** as the minimum passing score.
*45%*
- This value is significantly lower than the calculated lower bound of the 95% confidence interval (approximately 65.1%).
- It would represent a score far outside the defined passing range.
*63.75%*
- This value falls below the calculated lower bound of the 95% confidence interval (approximately 65.1%).
- While close, this score would not meet the professor's criterion for passing.
*67.5%*
- This value is within the 95% confidence interval (65.1% to 74.9%) but is **not the minimum score**.
- Lower scores within the interval would still qualify as passing.
*20%*
- This score is extremely low and falls significantly outside the 95% confidence interval for a mean of 70%.
- It would indicate performance far below the defined passing threshold.
NNT in screening programs US Medical PG Question 3: A 66-year-old gentleman presents to a new primary care physician to establish care after a recent relocation. His past medical history is significant for gout, erectile dysfunction, osteoarthritis of bilateral knees, mitral stenosis, and diabetic peripheral neuropathy. He denies any past surgeries along with the use of any tobacco, alcohol, or illicit drugs. He has no known drug allergies and cannot remember the names of the medications he is taking for his medical problems. He states that he has recently been experiencing chest pain with strenuous activities. What part of the patient's medical history must be further probed before starting him on a nitrate for chest pain?
- A. Erectile dysfunction (Correct Answer)
- B. Diabetic peripheral neuropathy
- C. Gout
- D. Arthritis
- E. Mitral stenosis
NNT in screening programs Explanation: ***Erectile dysfunction***
- Patients often take **phosphodiesterase-5 (PDE5) inhibitors** (e.g., sildenafil, tadalafil) for erectile dysfunction, which are absolutely contraindicated with nitrates.
- **Co-administration** can lead to a severe and potentially fatal drop in blood pressure due to enhanced vasodilation.
*Diabetic peripheral neuropathy*
- While important for overall health assessment, **diabetic peripheral neuropathy** does not directly contraindicate the use of nitrates for chest pain.
- It might influence medication choices if a patient has orthostatic hypotension, but not a direct contraindication.
*Gout*
- **Gout** is a joint condition and has no direct contraindication with nitrate use.
- Medications for gout, such as allopurinol or colchicine, do not interact adversely with nitrates.
*Arthritis*
- **Arthritis** (including osteoarthritis mentioned) is a musculoskeletal condition and does not contraindicate nitrate therapy.
- Pain management for arthritis does not typically involve drugs that interact dangerously with nitrates.
*Mitral stenosis*
- While **mitral stenosis** can affect cardiac function and hemodynamics, it is generally not an absolute contraindication to nitrate use.
- Nitrates can even be used cautiously in **mitral stenosis** to manage angina, though their use requires careful monitoring of preload.
NNT in screening programs US Medical PG Question 4: You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?
- A. 450 / (450 + 10)
- B. 490 / (10 + 490)
- C. 490 / (50 + 490)
- D. 450 / (450 + 50) (Correct Answer)
- E. 490 / (450 + 490)
NNT in screening programs Explanation: ***450 / (450 + 50)***
- **Sensitivity** is defined as the proportion of actual positive cases that are correctly identified by the test.
- In this study, there are **500 patients with colon cancer** (actual positives), and **450 of them tested positive** for the marker, while **50 tested negative** (500 - 450 = 50). Therefore, sensitivity = 450 / (450 + 50) = 450/500 = 0.9 or 90%.
*450 / (450 + 10)*
- This formula represents **Positive Predictive Value (PPV)**, which is the probability that a person with a positive test result actually has the disease.
- It incorrectly uses the total number of **test positives** in the denominator (450 true positives + 10 false positives) instead of the total number of diseased individuals, which is needed for sensitivity.
*490 / (10 + 490)*
- This is actually the correct formula for **specificity**, not sensitivity.
- Specificity = TN / (FP + TN) = 490 / (10 + 490) = 490/500 = 0.98 or 98%, which measures the proportion of actual negative cases correctly identified.
- The question asks for sensitivity, not specificity.
*490 / (50 + 490)*
- This formula incorrectly mixes **true negatives (490)** with **false negatives (50)** in an attempt to calculate specificity.
- The correct specificity formula should use false positives (10), not false negatives (50), in the denominator: 490 / (10 + 490).
*490 / (450 + 490)*
- This calculation incorrectly combines **true negatives (490)** and **true positives (450)** in the denominator, which does not correspond to any standard epidemiological measure.
- Neither sensitivity nor specificity uses both true positives and true negatives in the denominator.
NNT in screening programs US Medical PG Question 5: The APPLE study investigators are currently preparing for a 30-year follow-up evaluation. They are curious about the number of participants who will partake in follow-up interviews. The investigators noted that of the 83 participants who participated in the APPLE study's 20-year follow-up, 62 were in the treatment group and 21 were in the control group. Given the unequal distribution of participants between groups at follow-up, this finding raises concerns for which of the following?
- A. Volunteer bias
- B. Reporting bias
- C. Inadequate sample size
- D. Attrition bias (Correct Answer)
- E. Lead-time bias
NNT in screening programs Explanation: ***Attrition bias***
- **Attrition bias** occurs when participants drop out of a study, especially if the dropout rate differs between the intervention and control groups, which can lead to a **skewed comparison** of outcomes.
- The unequal distribution of participants (62 vs. 21) between the treatment and control groups at the 20-year follow-up suggests that a disproportionate number of participants may have dropped out of one group, thus leading to attrition bias.
*Volunteer bias*
- **Volunteer bias** occurs when individuals who volunteer for a study differ significantly from the general population or those who decline to participate, potentially affecting the study's **generalizability**.
- This scenario describes differences in retention *after* initial participation, not differences in initial willingness to join.
*Reporting bias*
- **Reporting bias** refers to the selective reporting of study findings, where positive or statistically significant results are more likely to be published or emphasized than negative or non-significant ones, which can distort the overall evidence base.
- This bias relates to how results are disseminated, not to differential dropout rates or participant retention in a study.
*Inadequate sample size*
- **Inadequate sample size** means that the number of participants in a study is too small to detect a statistically significant effect if one truly exists, leading to a lack of **statistical power**.
- While the overall number of participants at follow-up might be small, the primary concern here is the *unequal distribution* between groups, indicating a problem with participant retention rather than just a low total count.
*Lead-time bias*
- **Lead-time bias** occurs when early detection of a disease (e.g., through screening) makes survival appear longer than it actually is, without necessarily prolonging the patient's life, by advancing the **point of diagnosis**.
- This bias is relevant to screening programs and disease detection, not to the differential dropout rates observed in a longitudinal study.
NNT in screening programs US Medical PG Question 6: An epidemiologist is evaluating the efficacy of Noxbinle in preventing HCC deaths at the population level. A clinical trial shows that over 5 years, the mortality rate from HCC was 25% in the control group and 15% in patients treated with Noxbinle 100 mg daily. Based on this data, how many patients need to be treated with Noxbinle 100 mg to prevent, on average, one death from HCC?
- A. 20
- B. 73
- C. 10 (Correct Answer)
- D. 50
- E. 100
NNT in screening programs Explanation: ***10***
- The **number needed to treat (NNT)** is calculated by first finding the **absolute risk reduction (ARR)**.
- **ARR** = Risk in control group - Risk in treatment group = 25% - 15% = **10%** (or 0.10).
- **NNT = 1 / ARR** = 1 / 0.10 = **10 patients**.
- This means that **10 patients must be treated with Noxbinle to prevent one death from HCC** over 5 years.
*20*
- This would result from an ARR of 5% (1/0.05 = 20), which is not supported by the data.
- May arise from miscalculating the risk difference or incorrectly halving the actual ARR.
*73*
- This value does not correspond to any standard calculation of NNT from the given mortality rates.
- May result from confusion with other epidemiological measures or calculation error.
*50*
- This would correspond to an ARR of 2% (1/0.02 = 50), which significantly underestimates the actual risk reduction.
- Could result from incorrectly calculating the difference as a proportion rather than absolute percentage points.
*100*
- This would correspond to an ARR of 1% (1/0.01 = 100), grossly underestimating the treatment benefit.
- May result from confusing ARR with relative risk reduction or other calculation errors.
NNT in screening programs US Medical PG Question 7: A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?
- A. Tertiary prevention
- B. Primary prevention
- C. Secondary prevention (Correct Answer)
- D. Cancer screening does not fit into these categories
- E. Quaternary prevention
NNT in screening programs Explanation: ***Secondary prevention***
- **Secondary prevention** aims to detect and treat a disease early, before symptoms appear, to prevent its progression or recurrence.
- **Cancer screening tests** such as mammograms, colonoscopies, and Pap smears fit this category perfectly as they are performed in asymptomatic individuals to identify early-stage cancer or pre-cancerous lesions.
*Tertiary prevention*
- **Tertiary prevention** focuses on minimizing the impact of an established disease and improving quality of life through treatment and rehabilitation.
- This would involve managing existing cancer, not screening for it.
*Primary prevention*
- **Primary prevention** aims to prevent a disease from occurring in the first place, often through health promotion and risk reduction.
- Examples include vaccination, lifestyle modifications (e.g., healthy diet, exercise), or avoiding smoking.
*Cancer screening does not fit into these categories*
- This statement is incorrect as cancer screening is a well-established component of preventive healthcare.
- It clearly falls within the defined categories of prevention, specifically secondary prevention.
*Quaternary prevention*
- **Quaternary prevention** aims to protect patients from medical interventions that are likely to cause more harm than good, or to avoid over-medicalization.
- This concept is distinct from screening for diseases and focuses on ethical considerations in medical care.
NNT in screening programs US Medical PG Question 8: A 28-year-old male presents to his primary care physician with complaints of intermittent abdominal pain and alternating bouts of constipation and diarrhea. His medical chart is not significant for any past medical problems or prior surgeries. He is not prescribed any current medications. Which of the following questions would be the most useful next question in eliciting further history from this patient?
- A. "Does the diarrhea typically precede the constipation, or vice-versa?"
- B. "Is the diarrhea foul-smelling?"
- C. "Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life"
- D. "Are the symptoms worse in the morning or at night?"
- E. "Can you tell me more about the symptoms you have been experiencing?" (Correct Answer)
NNT in screening programs Explanation: ***Can you tell me more about the symptoms you have been experiencing?***
- This **open-ended question** encourages the patient to provide a **comprehensive narrative** of their symptoms, including details about onset, frequency, duration, alleviating/aggravating factors, and associated symptoms, which is crucial for diagnosis.
- In a patient presenting with vague, intermittent symptoms like alternating constipation and diarrhea, allowing them to elaborate freely can reveal important clues that might not be captured by more targeted questions.
*Does the diarrhea typically precede the constipation, or vice-versa?*
- While knowing the sequence of symptoms can be helpful in understanding the **pattern of bowel dysfunction**, it is a very specific question that might overlook other important aspects of the patient's experience.
- It prematurely narrows the focus without first obtaining a broad understanding of the patient's overall symptomatic picture.
*Is the diarrhea foul-smelling?*
- Foul-smelling diarrhea can indicate **malabsorption** or **bacterial overgrowth**, which are important to consider in some gastrointestinal conditions.
- However, this is a **specific symptom inquiry** that should follow a more general exploration of the patient's symptoms, as it may not be relevant if other crucial details are missed.
*Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life*
- Quantifying pain intensity is useful for assessing the **severity of discomfort** and monitoring changes over time.
- However, for a patient with intermittent rather than acute, severe pain, understanding the **character, location, and triggers** of the pain is often more diagnostically valuable than just a numerical rating initially.
*Are the symptoms worse in the morning or at night?*
- Diurnal variation can be relevant in certain conditions, such as inflammatory bowel diseases where nocturnal symptoms might be more concerning, or functional disorders whose symptoms might be stress-related.
- This is another **specific question** that should come after gathering a more complete initial picture of the patient's symptoms to ensure no key information is overlooked.
NNT in screening programs US Medical PG Question 9: A group of gastroenterologists is concerned about low colonoscopy screening rates. They decide to implement a free patient navigation program to assist local residents and encourage them to obtain colonoscopies in accordance with U.S. Preventive Services Task Force (USPSTF) guidelines. Local residents were recruited at community centers. Participants attended monthly meetings with patient navigators and were regularly reminded that their adherence to screening guidelines was being evaluated. Colonoscopy screening rates were assessed via chart review, which showed that 90% of participants adhered to screening guidelines. Data collected via chart review for local residents recruited at community centers who did not participate in the free patient navigation system found that 34% of that population adhered to USPSTF guidelines. Which of the following has most likely contributed to the observed disparity in colonoscopy screening rates?
- A. Recall bias
- B. Confirmation bias
- C. Reporting bias
- D. Hawthorne effect (Correct Answer)
- E. Sampling bias
NNT in screening programs Explanation: ***Hawthorne effect***
- The **Hawthorne effect** is a type of reactivity in which individuals modify an aspect of their behavior in response to their awareness of being observed.
- In this study, participants were aware that their adherence to screening guidelines was being evaluated, likely leading to increased compliance simply due to this awareness rather than the efficacy of the patient navigation program alone.
*Recall bias*
- **Recall bias** occurs when participants disproportionately remember or inaccurately recall past events, often due to their current health status or beliefs.
- This bias is less likely here as colonoscopy screening rates were assessed via **chart review**, an objective measure, rather than participant self-report.
*Confirmation bias*
- **Confirmation bias** is the tendency to search for, interpret, favor, and recall information in a way that confirms one's preexisting beliefs or hypotheses.
- This bias typically affects the researchers or observers, not the participants' behavior in the observed manner, as the question focuses on the participants' increased screening rates.
*Reporting bias*
- **Reporting bias** refers to selective revealing or suppression of information during the reporting of research findings, and can occur when study participants selectively report symptoms or behaviors.
- While participants might selectively report, the data here was gathered through **chart review**, which is a more objective measure of actual behavior, making reporting bias less likely to explain the disparity in screening rates.
*Sampling bias*
- **Sampling bias** occurs when a sample is not representative of the population from which it is drawn, leading to skewed results.
- While there might be some sampling bias in who chose to participate in the free program, the observed disparity is specifically about behavior change in those *being observed*, pointing more strongly to the Hawthorne effect.
NNT in screening programs US Medical PG Question 10: Many large clinics have noticed that the prevalence of primary biliary cholangitis (PBC) has increased significantly over the past 20 years. An epidemiologist is working to identify possible reasons for this. After analyzing a series of nationwide health surveillance databases, the epidemiologist finds that the incidence of PBC has remained stable over the past 20 years. Which of the following is the most plausible explanation for the increased prevalence of PBC?
- A. Improved quality of care for PBC (Correct Answer)
- B. Increased availability of diagnostic testing for PBC
- C. Increased exposure to environmental risk factors for PBC
- D. Increased awareness of PBC among clinicians
- E. Increased average age of the population at risk for PBC
NNT in screening programs Explanation: ***Improved quality of care for PBC***
- This leads to a **longer survival time** for patients with PBC. When incidence remains stable but patients live longer, the cumulative number of living cases (prevalence) naturally increases.
- An increase in prevalence with stable incidence is a classic indicator of **improved patient survival** due to better management or treatment.
*Increased availability of diagnostic testing for PBC*
- This would primarily impact the **incidence** of PBC by detecting more cases that were previously undiagnosed. The question states that the incidence has remained stable.
- While improved diagnostics might initially increase *reported* incidence, if the true incidence is stable, it wouldn't explain a sustained rise in prevalence without a corresponding change in incidence or survival.
*Increased exposure to environmental risk factors for PBC*
- This would directly lead to an **increase in the incidence** of PBC, as more people would be developing the disease.
- Since the incidence is stable, an increase in environmental risk factors is not the most plausible explanation for increased prevalence.
*Increased awareness of PBC among clinicians*
- Similar to increased diagnostic testing, increased awareness would likely lead to the diagnosis of more new cases, thus **increasing the incidence** of PBC.
- A stable incidence despite increased awareness means that the actual rate of new cases developing the disease has not changed, ruling this out as the primary cause of increased prevalence.
*Increased average age of the population at risk for PBC*
- An aging population could potentially increase the incidence of age-related diseases. However, if the **incidence has remained stable**, it implies that even with an older population, the rate of new diagnoses has not increased.
- While age is a risk factor for PBC, an increase in prevalence without a change in incidence suggests a factor influencing the duration of the disease rather than its onset.
More NNT in screening programs US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
